COMPASS Granted Patent of Psilocybin Formulation for Treatment-Resistant Depression

COMPASS Pathways has been granted US Patent No 10,519,175, relating to methods of treating drug-resistant depression with a psilocybin formulation, by the US Patent and Trademark Office (USPTO). The patent covers the use of COMPASS's synthesized investigational psilocybin formulation, COMP360, in a psilocybin therapy protocol for patients with treatment-resistant depression. Psilocybin is an active ingredient in so-called 'magic mushrooms'.

Last month, COMPASS reported that COMP360 was well tolerated when administered to healthy adult volunteers with support from specially trained therapists in a randomized placebo-controlled trial. COMPASS is currently running a phase IIb clinical trial of COMP360 in treatment-resistant depression. This trial is recruiting 216 patients from across Europe and North America who suffer with depression that hasn't responded to established medications, and will be the largest clinical trial of a psilocybin formulation to date. In 2018, COMPASS received FDA "Breakthrough Therapy" designation for its program of psilocybin therapy for treatment-resistant depression.

"Too many people are suffering with treatment resistant depression. We are committed to developing innovations, such as psilocybin therapy, to address this rapidly growing problem," George Goldsmith, CEO and Co-founder, COMPASS Pathways, said. "Patents help ensure sustainable funding to conduct the highest quality clinical research to bring the best new therapies to patients who urgently need them. If this research demonstrates psilocybin therapy is a safe and effective option for patients, we will price it responsibly with the goal of making it as affordable and accessible as possible."

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.